Literature DB >> 2496060

Amplification of both c-myc and c-raf-1 oncogenes in a human osteosarcoma.

S Ikeda1, H Sumii, K Akiyama, S Watanabe, S Ito, H Inoue, H Takechi, G Tanabe, T Oda.   

Abstract

Fourteen human bone and soft part tumor tissues were screened by Southern blot hybridization using five oncogene probes (c-myc, c-K-ras, c-fos, c-raf-1, and N-myc). Amplification of c-myc was found in two osteosarcomas and one malignant fibrous histiocytoma. One of these osteosarcomas had amplified c-raf-1 gene. Rearrangement of the amplified gene was not observed. This is the first report of c-raf-1 amplification in human cancer tissues.

Entities:  

Mesh:

Year:  1989        PMID: 2496060      PMCID: PMC5917676          DOI: 10.1111/j.1349-7006.1989.tb02236.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  14 in total

1.  The complete coding sequence of the human raf oncogene and the corresponding structure of the c-raf-1 gene.

Authors:  T I Bonner; H Oppermann; P Seeburg; S B Kerby; M A Gunnell; A C Young; U R Rapp
Journal:  Nucleic Acids Res       Date:  1986-01-24       Impact factor: 16.971

2.  Activation of human c-raf-1 by replacing the N-terminal region with different sequences.

Authors:  T Tahira; M Ochiai; K Hayashi; M Nagao; T Sugimura
Journal:  Nucleic Acids Res       Date:  1987-06-25       Impact factor: 16.971

Review 3.  Cellular oncogenes and human carcinogenesis.

Authors:  C J Der
Journal:  Clin Chem       Date:  1987-05       Impact factor: 8.327

4.  Activation of human raf transforming genes by deletion of normal amino-terminal coding sequences.

Authors:  V P Stanton; G M Cooper
Journal:  Mol Cell Biol       Date:  1987-03       Impact factor: 4.272

5.  Onc gene amplification in promyelocytic leukaemia cell line HL-60 and primary leukaemic cells of the same patient.

Authors:  R Dalla-Favera; F Wong-Staal; R C Gallo
Journal:  Nature       Date:  1982-09-02       Impact factor: 49.962

6.  Amplifications of both c-Ki-ras with a point mutation and c-myc in a primary pancreatic cancer and its metastatic tumors in lymph nodes.

Authors:  H Yamada; H Sakamoto; M Taira; S Nishimura; Y Shimosato; M Terada; T Sugimura
Journal:  Jpn J Cancer Res       Date:  1986-04

7.  Activation of rat c-raf during transfection of hepatocellular carcinoma DNA.

Authors:  F Ishikawa; F Takaku; K Hayashi; M Nagao; T Sugimura
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

8.  The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma.

Authors:  J Battey; C Moulding; R Taub; W Murphy; T Stewart; H Potter; G Lenoir; P Leder
Journal:  Cell       Date:  1983-10       Impact factor: 41.582

9.  Molecular cloning of an activated human oncogene, homologous to v-raf, from primary stomach cancer.

Authors:  K Shimizu; Y Nakatsu; M Sekiguchi; K Hokamura; K Tanaka; M Terada; T Sugimura
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

10.  A novel combination of K-ras and myc amplification accompanied by point mutational activation of K-ras in a human lung cancer.

Authors:  Y Taya; K Hosogai; S Hirohashi; Y Shimosato; R Tsuchiya; N Tsuchida; M Fushimi; T Sekiya; S Nishimura
Journal:  EMBO J       Date:  1984-12-01       Impact factor: 11.598

View more
  13 in total

Review 1.  Selective Raf inhibition in cancer therapy.

Authors:  Vladimir Khazak; Igor Astsaturov; Ilya G Serebriiskii; Erica A Golemis
Journal:  Expert Opin Ther Targets       Date:  2007-12       Impact factor: 6.902

Review 2.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

3.  Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma.

Authors:  Venugopal Thayanithy; Aaron L Sarver; Reena V Kartha; Lihua Li; Andrea Y Angstadt; Matthew Breen; Clifford J Steer; Jaime F Modiano; Subbaya Subramanian
Journal:  Bone       Date:  2011-10-18       Impact factor: 4.398

4.  Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors.

Authors:  K Scotlandi; N Baldini; M Oliviero; M F Di Renzo; M Martano; M Serra; M C Manara; P M Comoglio; R Ferracini
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

5.  MicroRNA-561 inhibits gastric cancercell proliferation and invasion by downregulating c-Myc expression.

Authors:  Kun Qian; Binglang Mao; Wei Zhang; Huanwen Chen
Journal:  Am J Transl Res       Date:  2016-09-15       Impact factor: 4.060

6.  Two distinct cell lines derived from a human osteosarcoma.

Authors:  A Kawai; T Ozaki; S Ikeda; T Oda; M Miyazaki; J Sato; K Taketa; H Inoue
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

7.  Molecular alterations associated with osteosarcoma development.

Authors:  Kosei Ando; Kanji Mori; Franck Verrecchia; Baud'huin Marc; Françoise Rédini; Dominique Heymann
Journal:  Sarcoma       Date:  2012-02-15

8.  Amplification of the MYC Gene in Osteosarcoma Secondary to Paget's Disease of Bone.

Authors:  T Ueda; J H Healey; A G Huvos; M Ladanyi
Journal:  Sarcoma       Date:  1997

9.  Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.

Authors:  Ymera Pignochino; Giovanni Grignani; Giuliana Cavalloni; Manuela Motta; Marta Tapparo; Stefania Bruno; Alessia Bottos; Loretta Gammaitoni; Giorgia Migliardi; Giovanni Camussi; Marco Alberghini; Bruno Torchio; Stefano Ferrari; Federico Bussolino; Franca Fagioli; Piero Picci; Massimo Aglietta
Journal:  Mol Cancer       Date:  2009-12-10       Impact factor: 27.401

10.  Comparative analysis of genome-wide DNA methylation identifies patterns that associate with conserved transcriptional programs in osteosarcoma.

Authors:  Lauren J Mills; Milcah C Scott; Pankti Shah; Anne R Cunanan; Archana Deshpande; Benjamin Auch; Bridget Curtin; Kenneth B Beckman; Logan G Spector; Aaron L Sarver; Subbaya Subramanian; Todd A Richmond; Jaime F Modiano
Journal:  Bone       Date:  2020-10-27       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.